How should I manage an adult patient whose blood glucose is 150–350 mg/dL despite using only a sliding‑scale insulin regimen?

Transition from Sliding‑Scale to Scheduled Basal‑Bolus Insulin Immediately

Discontinue sliding‑scale insulin as the sole regimen and initiate a scheduled basal‑bolus approach now, because blood glucose ranging 150–350 mg/dL on sliding‑scale monotherapy indicates complete therapeutic failure and is explicitly condemned by all major diabetes guidelines. 1, 2, 3

---

Why Sliding‑Scale Insulin Alone Fails

• Sliding‑scale insulin (SSI) reacts to hyperglycemia after it occurs rather than preventing it, creating a dangerous cycle of hyperglycemia → large correction dose → hypoglycemia → rebound hyperglycemia. 1, 3, 4
• Only ≈38 % of patients achieve mean glucose < 140 mg/dL with SSI alone, versus ≈68 % when a scheduled basal‑bolus regimen is used. 1, 3, 5
• SSI provides no basal insulin to suppress hepatic glucose production overnight and between meals, guaranteeing persistent fasting hyperglycemia. 1, 3
• SSI lacks scheduled prandial insulin, causing post‑meal glucose spikes that are later corrected with reactive doses, perpetuating poor control. 1, 3
• The American Diabetes Association and all major diabetes societies explicitly condemn SSI as monotherapy and recommend immediate discontinuation. 1, 2, 3, 6

---

Recommended Basal‑Bolus Regimen

Initial Dosing

• Total daily insulin dose: Start with 0.3–0.5 U/kg/day for patients with moderate‑to‑severe hyperglycemia (glucose 150–350 mg/dL). 1, 3, 6
• Basal insulin: Allocate 50 % of the total dose to a long‑acting analog (glargine, detemir, or degludec) given once daily at bedtime or morning. 1, 3, 6
• Prandial insulin: Allocate the remaining 50 % to rapid‑acting insulin (lispro, aspart, or glulisine) divided equally among three meals, administered 0–15 minutes before eating. 1, 3, 6
• Correction doses: Add 2 U for pre‑meal glucose > 250 mg/dL and 4 U for glucose > 350 mg/dL, in addition to scheduled prandial insulin—never as a replacement. 1, 2, 6

Example for a 70‑kg Adult

• Total daily dose: 0.4 U/kg × 70 kg = 28 U/day. 1, 6
• Basal insulin: 14 U glargine once daily at bedtime. 1, 6
• Prandial insulin: 4–5 U lispro before breakfast, lunch, and dinner. 1, 6
• Correction scale: 2 U for glucose > 250 mg/dL, 4 U for glucose > 350 mg/dL, added to scheduled prandial doses. 1, 2, 6

---

Titration Protocol

Basal Insulin

• If fasting glucose 140–179 mg/dL: Increase basal dose by 2 U every 3 days. 1, 6
• If fasting glucose ≥180 mg/dL: Increase basal dose by 4 U every 3 days. 1, 6
• Target fasting glucose: 80–130 mg/dL. 1, 6
• If glucose < 70 mg/dL: Reduce the implicated insulin dose by 10–20 % immediately. 1, 6

Prandial Insulin

• Increase each meal dose by 1–2 U (≈10–15 %) every 3 days based on 2‑hour post‑prandial glucose readings. 1, 6
• Target post‑prandial glucose: < 180 mg/dL. 1, 6

---

Monitoring Requirements

• Fasting glucose: Check daily to guide basal insulin adjustments. 1, 6
• Pre‑meal glucose: Measure before each meal to calculate correction doses. 1, 6
• 2‑hour post‑prandial glucose: Obtain after each meal to assess prandial adequacy. 1, 6
• Bedtime glucose: Record to evaluate overall daily pattern. 1, 6
• Reassess insulin doses every 3 days while actively titrating. 1, 6

---

Expected Clinical Outcomes

• With a properly implemented basal‑bolus regimen, ≈68 % of patients achieve mean glucose < 140 mg/dL, compared with ≈38 % on SSI alone. 1, 3, 5
• Basal‑bolus therapy does not increase hypoglycemia incidence when titrated per protocol, unlike inadequate SSI regimens. 1, 3, 5
• HbA1c reductions of 2–3 % are achievable within 3–6 months with intensive insulin titration. 1

---

Critical Pitfalls to Avoid

• Do not continue SSI as monotherapy when glucose repeatedly exceeds 180 mg/dL; it is inferior and unsafe. 1, 2, 3, 6
• Do not delay adding prandial insulin when basal insulin alone fails to meet fasting glucose targets. 1, 6
• Never use rapid‑acting insulin at bedtime as a sole correction dose, as it markedly raises nocturnal hypoglycemia risk. 1, 6
• Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin; this perpetuates inadequate control. 1, 2, 6

---

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed. 1, 6
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 1, 6

---

Special Considerations for Hospitalized Patients

• For hospitalized patients with good oral intake, use a full basal‑bolus regimen with basal, prandial, and correction components. 2, 3, 6
• For patients with poor or no oral intake, use a basal‑plus approach with basal insulin and correction doses only, checking glucose every 4–6 hours. 2, 3, 6
• Target glucose range for hospitalized patients: 140–180 mg/dL for most non‑critically ill patients. 2, 6

---

Adjunctive Therapy

• Continue metformin at the maximum tolerated dose (up to ≈2,500 mg daily) when initiating insulin; metformin reduces total insulin requirements by 20–30 % and improves glycemic control. 1
• Discontinue sulfonylureas when starting basal‑bolus insulin to avoid additive hypoglycemia risk. 1